Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma.
<h4>Background</h4> <p>Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict re...
Main Authors: | Lee, R, Gremel, G, Marshall, A, Myers, K, Fisher, N, Dunn, J, Dhomen, N, Corrie, P, Middleton, M, Lorigan, P, Marais, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Oxford University Press
2017
|
Similar Items
-
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
by: Lipplaa, A, et al.
Published: (2018) -
Circulating melanoma cells and survival in metastatic melanoma.
by: Rao, C, et al.
Published: (2011) -
Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol
by: Lionnel Geoffrois, et al.
Published: (2023-06-01) -
Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma
by: Andrew B Gill, et al.
Published: (2020-11-01) -
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
by: Hancock, B, et al.
Published: (2004)